- Home
- INCY vs GDDY Comparison
INCY vs GDDY Comparison
Compare INCY & GDDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- GDDY
- Stock Information
- Founded
- INCY 1991
- GDDY 1997
- Country
- INCY United States
- GDDY United States
- Employees
- INCY N/A
- GDDY N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- GDDY EDP Services
- Sector
- INCY Health Care
- GDDY Technology
- Exchange
- INCY Nasdaq
- GDDY Nasdaq
- Market Cap
- INCY 17.0B
- GDDY 20.0B
- IPO Year
- INCY 1993
- GDDY 2015
- Fundamental
- Price
- INCY $105.96
- GDDY $131.15
- Analyst Decision
- INCY Buy
- GDDY Buy
- Analyst Count
- INCY 19
- GDDY 14
- Target Price
- INCY $89.19
- GDDY $189.71
- AVG Volume (30 Days)
- INCY 2.9M
- GDDY 1.4M
- Earning Date
- INCY 10-28-2025
- GDDY 10-30-2025
- Dividend Yield
- INCY N/A
- GDDY N/A
- EPS Growth
- INCY 3878.02
- GDDY N/A
- EPS
- INCY 5.90
- GDDY 5.80
- Revenue
- INCY $4,813,105,000.00
- GDDY $4,869,800,000.00
- Revenue This Year
- INCY $19.33
- GDDY $10.16
- Revenue Next Year
- INCY $10.47
- GDDY $6.99
- P/E Ratio
- INCY $18.34
- GDDY $22.85
- Revenue Growth
- INCY 18.09
- GDDY 8.68
- 52 Week Low
- INCY $53.56
- GDDY $125.00
- 52 Week High
- INCY $109.28
- GDDY $216.00
- Technical
- Relative Strength Index (RSI)
- INCY 73.65
- GDDY 44.90
- Support Level
- INCY $91.16
- GDDY $128.73
- Resistance Level
- INCY $109.28
- GDDY $136.29
- Average True Range (ATR)
- INCY 4.54
- GDDY 3.54
- MACD
- INCY 0.92
- GDDY 0.44
- Stochastic Oscillator
- INCY 86.44
- GDDY 49.35
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About GDDY GoDaddy Inc.
GoDaddy provides domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.